Number of Shares and Voting Rights of ADOCIA as of November 30, 2020
December 07 2020 - 11:00AM
Business Wire
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French
« Code de Commerce » and article 223-16 of the French stock-market
authorities (Autorité des Marchés Financiers, or “AMF”) charter
ADOCIA SA (Paris:ADOC), a French société anonyme (corporation),
115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 –
ADOC) a clinical stage biopharmaceutical company focused on
diabetes treatment with innovative formulations of approved
proteins, releases its total number of outstanding shares as well
as its voting rights as of November 30, 2020.
Month
Date
Total number of outstanding
shares
Total number of theoretical
voting rights (1)
Total number of exercisable
voting ights (2)
November
11/30/2020
6 978 754
9 742 469
9 709 868
(1) The total number of theoretical voting rights (or “gross”
voting rights) is used as the basis for calculating the crossing of
shareholding thresholds. In accordance with Article 223-11 of the
AMF General Regulation, this number is calculated on the basis of
all shares to which voting rights are attached, including shares
whose voting rights have been suspended.
(2) The total number of exercisable voting rights (or” net”
voting rights) is calculated without taking into account the shares
with suspended voting rights, in this case, shares held by the
Company in the context of a liquidity agreement.
About ADOCIA
ADOCIA is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, ADOCIA’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring four clinical-stage products. ADOCIA
aims to expand its portfolio towards the treatment of other
metabolic diseases and their comorbidities. The proprietary
BioChaperone® technological platform is designed to enhance the
effectiveness and/or safety of therapeutic proteins while making
them easier for patients to use. ADOCIA customizes BioChaperone to
each protein for a given application.
ADOCIA’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid-acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram (ADO09). The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
ADOCIA preclinical pipeline includes three products: a
combination of rapid human insulin analogues and Pramlintide
(BioChaperone LisPram), a combination of insulin glargine with
GLP-1 receptor agonists (BioChaperone® Glargine GLP-1) for the
treatment of diabetes and a ready-to-use combination of glucagon
and a GLP-1 receptor agonist (BioChaperone® Glucagon GLP1) for the
treatment of obesity.
Disclaimer
This press release contains certain forward-looking statements
concerning ADOCIA and its business. Such forward-looking statements
are based on assumptions that ADOCIA considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Reference Document filed with the
French Autorité des marchés financiers on April 22, 2020 (a copy of
which is available at www.adocia.com) and to the development of
economic conditions financial markets and the markets in which
ADOCIA operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Adocia or
not currently considered material by Adocia. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance, or achievements of ADOCIA to be materially
different from such forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
ADOCIA shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201207005752/en/
ADOCIA Gérard Soula CEO
contactinvestisseurs@adocia.com Ph: +33 4 72 610 610
www.adocia.com
MC Services AG ADOCIA Press Relations Europe
Raimund Gabriel Managing Partner adocia@mc-services.eu Ph:
+49 89 210 228 0
The Ruth Group ADOCIA Investor Relations USA
James Salierno Vice-President jsalierno@theruthgroup.com
Ph.: +1 646 536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2024 to May 2024
Adocia (EU:ADOC)
Historical Stock Chart
From May 2023 to May 2024